Cats enter GLP‑1 weight trial
Cornell is recruiting client‑owned cats for an 11‑week trial of AKS‑562c — a once‑weekly GLP‑1 Fc‑fusion drug designed to curb appetite and measure safety and tolerability in feline weight management. (The trial’s goal is to see if weekly dosing produces clinically meaningful weight loss while tracking adverse effects in pets.) (dvm360.com)
Cats are joining the same drug wave humans did, but for a much older problem: Cornell says as many as 2 out of 3 cats weigh too much, and extra weight in cats is linked to diabetes, trouble moving, and shorter lives. (vet.cornell.edu) A glucagon-like peptide 1 drug is basically a chemical “I’m full” signal. In people, that signal is used to lower appetite and food intake, and Cornell says a similar idea is now being tested in pet cats. (vet.cornell.edu) The hard part in cats is not inventing a diet plan. The hard part is getting a cat to cooperate with a diet when the cat can still demand food at 5 a.m., raid another pet’s bowl, or wear down an owner with persistence. (vet.cornell.edu) Cornell’s trial is testing a drug called AKS-562c in client-owned cats, which means ordinary pets living at home instead of research animals in a lab. The study runs 11 weeks, with 10 weekly shots under the skin of either the drug or a placebo made of saline. (dvm360.com) (vet.cornell.edu) This is not just a “does the scale move” study. Cornell says it is tracking safety and tolerability while looking for clinically meaningful weight loss, because a cat that loses weight but vomits, stops eating, or feels miserable is not a useful treatment. (dvm360.com) (vet.cornell.edu) The drug is built as an Fc-fusion protein, which is a way of attaching the active part of a medicine to a larger protein scaffold so it stays in the body longer. Akston says that longer stay is what makes once-weekly dosing possible instead of more frequent injections. (akstonbio.com 1) (akstonbio.com 2) Cornell’s researchers say there are no published studies of glucagon-like peptide 1 drugs used for weight loss in cats. They also say preclinical work in laboratory cats found AKS-562c was safe and effective at limiting food intake, which is why the project has now moved into pets living in real homes. (vet.cornell.edu) That “real homes” part matters because home life is where feline weight control usually falls apart. A cat may share food with another animal, get treats from multiple people, or react badly to calorie cuts, so a drug that works in a controlled room still has to prove itself in a kitchen. (vet.cornell.edu) Akston says the cat program is ahead of a similar dog program by about six months, and the company is framing both as a new veterinary market rather than a one-off experiment. That means Cornell’s 11-week cat study is not just a campus project; it is part of an early push to turn the human weight-loss drug boom into pet medicine. (akstonbio.com) (dvm360.com) If the shots work, the pitch is simple: one injection a week that helps an overweight cat eat less without turning every meal into a household battle. If the side effects are too rough or the weight loss is too small, this will end up looking like one more reminder that cats are much harder patients than people. (vet.cornell.edu) (dvm360.com)
